Full-service clinicalRank #3 of 12Prescribes

Form Health

Item: Form Health
Rating: 8
Author: MyGLP Reviews

Board-certified obesity medicine delivered virtually

Founded 2019 · Boston, MA · Private · Website

8.0Strong

Weighted score

Strong

Reviewed September 19, 2026

PMPM benchmark

$58–$105

Category planning band — not a vendor quote. Excludes drug spend.

Our verdict

Buy it when clinical quality is the deciding criterion and you can pay for it. Validate prescriber capacity in your geography before committing a large population.

Scorecard

How it scored

Scored against the published rubric. Weights are fixed before review and identical for every vendor.

How scoring works

Clinical rigor9.1

Prescriber credentials, titration protocol, comorbidity screening, and off-ramp planning.

Outcomes evidence7.8

Quality of published results: peer review, sample size, control group, and follow-up duration.

Cost control7.5

Ability to hold net pharmacy spend down: gating, biosimilar strategy, and risk sharing.

Data & reporting7.4

Eligibility-level reporting, claims feeds, and whether you can audit the vendor's own numbers.

Integration7.0

PBM, carrier, HRIS, and point-solution interoperability without custom engineering.

Member experience8.2

Time to first appointment, app quality, care-team continuity, and support responsiveness.

Analysis

What we found

Form Health is the clinical quality benchmark in this evaluation. Requiring board certification in obesity medicine for every prescriber is a materially higher standard than any competitor holds, and it shows in the outcomes, which track closer to trial benchmarks than the real-world norm. That quality is priced accordingly, and physician-led staffing caps how quickly it can absorb a large population. Reporting and integration are functional but built for a clinical organization rather than a benefits analytics team.

Strengths

Every prescriber is board-certified in obesity medicine — the highest clinical bar of any vendor evaluated
Real-world outcomes track unusually close to trial benchmarks, which suggests genuine protocol discipline
Twelve-month term and 500-life minimum make serious clinical care accessible to mid-market buyers

Limitations

Physician-heavy staffing makes it one of the most expensive options per enrolled member
Integration and reporting are thinner than enterprise-oriented competitors
Specialist supply constrains how fast it can scale a large population

Best for

Employers who want the highest clinical quality available and can accept a premium PMPM to get it.

Watch out

Ask about prescriber capacity in your geography. Board-certified obesity medicine is a genuinely scarce specialty.

The details

Commercial and clinical specifics

The facts you will need to build a comparison grid. Verify each against the vendor's own documentation before contracting.

Pricing

Model: Per-enrolled-member monthly, clinical-visit-weighted
PMPM range: $58–$105
Setup fee: Typically $5k–15k
Medications included: No
Performance guarantees: Clinical outcome guarantees available above 2,000 lives

Contract

Minimum lives: 500
Term: 12 months
Termination notice: 60 days

Eligibility

BMI threshold: BMI ≥ 30, or ≥ 27 with comorbidity
Prior authorization: Yes
Step therapy: Yes
Comorbidity required: No

Clinical model

Prescribes: Yes
Care team: Board-certified obesity medicine physicians, Registered dietitians, Nurse practitioners
Titration protocol: Physician-led with obesity-medicine board certification required for all prescribers
Off-ramp: Physician-directed dose reduction with structured maintenance follow-up
Formulary: Semaglutide, Tirzepatide, Liraglutide, Phentermine, Bupropion/naltrexone, Metformin

Outcomes evidence

Headline claim: 19.4% average weight loss at 12 months and 20.3% at 24 months in peer-reviewed real-world analyses of its telehealth obesity clinic
Evidence level: Peer-reviewed observationalPublished cohort data, no randomization.
Sample size: Large-scale clinic cohorts across 12- and 24-month analyses
Follow-up: 12 months and 24 months, published separately

Sources

Twelve-month real-world evidence from a large-scale telehealth obesity clinic (PMC)8.9% at 3 months, 14.1% at 6 months and 19.4% at 12 months
Twenty-four month outcomes from a real-world telehealth cohort18.5% at 18 months and 20.3% at 24 months

Outcomes verified 2026-09-19. Pricing and contract figures on this page are category planning benchmarks, not vendor quotes — see methodology.

Integrations

PBMs: CVS Caremark, Express Scripts, Optum Rx
Carriers: Aetna, Cigna, UnitedHealthcare
HRIS: Workday, ADP, UKG
Eligibility file: 834 or flat file, weekly cadence

Formulary

Form Health by medication

How a vendor positions each molecule reveals more about its cost discipline than any single score. First-line means an eligible member can start immediately; escalation means a documented lower-cost trial comes first.

Form Health Reviews Semaglutide

GLP-1 receptor agonist

First-line

First-line, prescribed exclusively by physicians board-certified in obesity medicine — the highest clinical bar of any vendor evaluated. Protocol discipline shows up in real-world results tracking unusually close to trial benchmarks.

Read pairing

Form Health Reviews Tirzepatide

Dual GIP/GLP-1 receptor agonist

First-line

First-line alongside semaglutide, selected on clinical grounds by an obesity-medicine specialist rather than by formulary default. Physician-directed dose reduction is built into the maintenance plan.

Read pairing

Form Health Reviews Liraglutide

GLP-1 receptor agonist

First-line

Genuinely used rather than merely listed. Form's formulary breadth and specialist prescribers make it one of the few vendors that will place a member on a cheaper agent when it is clinically appropriate.

Read pairing